1. Introduction: Clinical Trial Registries

   • Tracy J. Beck
   • Barbara J. Godlew

   Clinical Trials 30 December 2010 Pages: 205 - 205

2. FDAAA: Unintended Consequences

   • Barbara J. Godlew

   Clinical Trials 30 December 2010 Pages: 207 - 212

3. Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines

   • Kathy B. Thomas
   • Merete Joergensen
   • Claudia Tesch

   Clinical Trials 30 December 2010 Pages: 213 - 225

4. The Emergence and Growth of Clinical Trial Information Transparency

   • Pamela A. Rose

   Clinical Trials 30 December 2010 Pages: 227 - 232

5. ClinicalTrials.gov: A Questionnaire of Industry Experiences and Perceptions

   • Katie McCarthy
   • Barbara J. Godlew

   Clinical Trials 30 December 2010 Pages: 233 - 241

6. Clinical Trial Registration and Results Disclosure: Business Process Considerations

   • Patricia Teden

   Clinical Trials 30 December 2010 Pages: 243 - 251

7. Operational Issues in Clinical Trial Disclosure of Global Trials

   • Shown M. Pelletier
   • Maureen A. Strange
   • Barbara J. Godlew

   Clinical Trials 30 December 2010 Pages: 253 - 264

8. Transparency as a Means to Increase Clinical Trial Enrollment

   • Barbara J. Godlew
   • Patricia Furlong

   Clinical Trials 30 December 2010 Pages: 265 - 270

9. Can Clinical Trial Results Databases and Manuscripts Coexist?

   • Tracy J. Beck

   Clinical Trials 30 December 2010 Pages: 271 - 277

10. Clinical Trial Registries: An Industry Perspective

    • Lia McLean

    Clinical Trials 30 December 2010 Pages: 279 - 287

11. Global and Regional Drug Regulatory Harmonization Initiatives

    • Maha M. Lakkis

    Regulatory Affairs 30 December 2010 Pages: 289 - 297

12. Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation

    • Norbert Benda
    • Michael Branson
    • Tim Friede

    Regulatory Affairs 30 December 2010 Pages: 299 - 315

13. Identifying and Rewarding Pharmaceutical Innovation: Application in an EU Member State

    • Philippe Van Wilder
    • Qi Zhu
    • Noël Veraverbeke

    Regulatory Affairs 30 December 2010 Pages: 317 - 323

14. From Adaptive Design to Modern Protocol Design for Drug Development: Part I. Editorial and Summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum

    • Sue-Jane Wang
    • Frank Bretz

    Statistics 30 December 2010 Pages: 325 - 331

15. From Adaptive Design to Modern Protocol Design for Drug Development: Part II. Success Probabilities and Effect Estimates for Phase 3 Development Programs

    • Frank Brefz
    • Sue-Jane Wang

    Statistics 30 December 2010 Pages: 333 - 342

16. Primary Efficacy Endpoint in Clinical Trials of Antiepileptic Drugs: Change or Percentage Change

    • Ohidul Siddiqui
    • Norman Hershkowitz

    Statistics 30 December 2010 Pages: 343 - 350